Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare LtdfiledCriticalCadila Healthcare Ltd
Priority claimed from PCT/IN2015/000063external-prioritypatent/WO2015132799A2/en
Publication of MA39153A1publicationCriticalpatent/MA39153A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La présente invention concerne des composés hétérocycliques de formule générale (i), leurs sels pharmaceutiquement acceptables, solvates pharmaceutiquement acceptables, énantiomères, diastéréoisomères, et polymorphes. L'invention concerne également des procédés de préparation de ces composés, des compositions pharmaceutiques contenant ces composés, et leur utilisation en tant qu'inhibiteurs sélectifs de la tyrosine kinase de bruton (btk).(i)The present invention relates to heterocyclic compounds of general formula (i), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereoisomers, and polymorphs. The invention also relates to processes for the preparation of these compounds, pharmaceutical compositions containing these compounds, and their use as selective inhibitors of broncine tyrosine kinase (btk).
MA39153A2014-07-112015-02-02
New heterocyclic compounds
MA39153A1
(en)